The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

The device provided herein is an organic electroluminescent device and includes a substrate; a first electrode on the substrate and with high reflectivity; a translucent or transparent second electrode over the first electrode; and a first, a second and a third organic layer included between the first and the second electrode; where the second organic layer has a thickness >80 nm and is made of a second organic material; the third organic layer is a light-emitting layer including at least one light-emitting material and at least one host material; the first organic layer has a conductivity >1×10.sup.−4 S/m and <1×10.sup.−2 S/m; an energy level difference between HOMO energy level of the second organic material and HOMO energy level of the at least one host material is <0.27 eV; and the first electrode and the second organic layer are in direct contact with the first organic layer.

The device provided herein is an organic electroluminescent device and includes a substrate; a first electrode on the substrate and with high reflectivity; a translucent or transparent second electrode over the first electrode; and a first, a second and a third organic layer included between the first and the second electrode; where the second organic layer has a thickness >80 nm and is made of a second organic material; the third organic layer is a light-emitting layer including at least one light-emitting material and at least one host material; the first organic layer has a conductivity >1×10.sup.−4 S/m and <1×10.sup.−2 S/m; an energy level difference between HOMO energy level of the second organic material and HOMO energy level of the at least one host material is <0.27 eV; and the first electrode and the second organic layer are in direct contact with the first organic layer.

The present invention relates to a triazine compound according to formula 1: suitable for use as a layer material for electronic devices, and to an organic semiconductor layer comprising at least one compound according to formula 1, as well as to an organic electronic device comprising at least one organic semiconductor layer, and a method of manufacturing the same. ##STR00001##

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q.sup.1, Q.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals. ##STR00001##

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q.sup.1, Q.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals. ##STR00001##

The instant invention describes compounds having IL-6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).